Slika na naslovnici

Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells

One of the main problems of modern health care is the growing number of oncological diseases both in the elderly and young population. Inadequately effective chemotherapy, which remains the main method of cancer control, is largely associated with the emergence of multidrug resistance in tumor cells...

Shranjeno v:

Bibliografske podrobnosti
Main Authors:	Natalia Todosenko (Author), Kristina Yurova (Author), Olga Khaziakhmatova (Author), Vladimir Malashchenko (Author), Igor Khlusov (Author), Larisa Litvinova (Author)
Format:	Knjiga
Izdano:	MDPI AG, 2022-10-01T00:00:00Z.
Teme:	article
Online dostop:	Connect to this object online.
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
od: Janis Kay Shute
Izdano: (2023)

Effects of low-molecular-weight heparin and unfractionated heparin on patients with exertional heat stroke with thrombocytopenia: A prospective study
od: Li Cheng, et al.
Izdano: (2019)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
od: Alessandra F. Perna, et al.
Izdano: (2020)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
od: Leping Liu, et al.
Izdano: (2023)

Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study
od: Danielle Green, et al.
Izdano: (2024)

Heparin interferes with the uptake of liposomes in glioma
od: Thomas S. van Solinge, et al.
Izdano: (2023)

Cutaneous secondary localization of multiple myeloma at Heparin injection sites
od: Emma Borg, et al.
Izdano: (2023)

Assessment of the effects of low molecular heparins in pulmonary embolism prophylaxis
od: Michał Piwoński, et al.
Izdano: (2019)

Assessment of the effects of low molecular heparins in pulmonary embolism prophylaxis
od: Michał Piwoński, et al.
Izdano: (2019)

Low molecular weight heparin in COVID-19: benefits and concerns
od: Adham Makarem, et al.
Izdano: (2023)

An Ovarian Cancer Patient Presenting Heparin - Induced Thrombocytopenia after use of Low - Molecular - Weight Heparin: A Case Report of Rare Condition
od: Yasin Durmuş, et al.
Izdano: (2019)

Heparin Mimetics: Their Therapeutic Potential
od: Shifaza Mohamed, et al.
Izdano: (2017)

Heparin: Past, Present, and Future
od: Eziafa I. Oduah, et al.
Izdano: (2016)

To be or not to be a case of heparin resistance
od: Jibran Durrani, et al.
Izdano: (2018)

HEPARIN-INDUCED THROMBOCYTOPENIA (REVIEW)
od: S. A. Vasiliev, et al.
Izdano: (2019)

pH-Sensitive Chitosan-Heparin Nanoparticles for Effective Delivery of Genetic Drugs into Epithelial Cells
od: Iuliia Pilipenko, et al.
Izdano: (2019)

Repurposing Heparin as Antimalarial: Evaluation of Multiple Modifications Toward In Vivo Application
od: Elena Lantero, et al.
Izdano: (2020)

Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review
od: Ke Feng, et al.
Izdano: (2023)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
od: Alex C Spyropoulos, et al.
Izdano: (2008)

Heparin Induced Osteoporosis Following Pregnancy
od: Pınar Akpınar, et al.
Izdano: (2016)

Heparin-Induced Thrombocytopenia in COVID-19
od: Prasanth Lingamaneni MD, et al.
Izdano: (2020)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
od: Pasquale Paolisso, et al.
Izdano: (2020)

Development of subcutaneous sustained release nanoparticles encapsulating low molecular weight heparin
od: Satheesh Jogala, et al.
Izdano: (2015)

Strategies to Overcome Heparins' Low Oral Bioavailability
od: Ana Rita Neves, et al.
Izdano: (2016)

High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin
od: Michela eAsperti, et al.
Izdano: (2016)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
od: Sergio Siragusa
Izdano: (2011)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
od: Sergio Siragusa
Izdano: (2011)

Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
od: Shingo Nakamura, et al.
Izdano: (2012)

Anticoagulant, anti-inflammatory, antiviral and antitumor properties of heparins
od: V. O. Bitsadze, et al.
Izdano: (2021)

Advanced delivery strategies facilitating oral absorption of heparins
od: Guihua Fang, et al.
Izdano: (2020)

Life-threatening hemorrhage following subcutaneous heparin therapy
od: Jana Hudcova, et al.
Izdano: (2008)

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy
od: Razia Sultana, et al.
Izdano: (2024)

Heparin Mimetics and Their Impact on Extracellular Matrix Protein Assemblies
od: Fabian Heide, et al.
Izdano: (2023)

Tips on drawing blood through a heparin lock
od: Akram Ghaemmaghami
Izdano: (1993)

POSSIBILITIES OF USING LOW-MOLECULAR-WEIGHT HEPARIN IN THE COMPLEX TREATMENT OF WOMEN WITH TUMORS OF THE REPRODUCTIVE SYSTEM
od: A. G. Kedrova, et al.
Izdano: (2017)

Effects of Enzymatically Depolymerized Low Molecular Weight Heparins on CCl4-Induced Liver Fibrosis
od: Yishu Yan, et al.
Izdano: (2017)

Case Report: Spontaneous Intramural Hematoma of the Colon Secondary to Low Molecular Weight Heparin Therapy
od: Ye Zhu, et al.
Izdano: (2021)

Durability of the two-lumen catheter in hemodialysis patients; Ethanol 70%-heparin versus cefazolin-heparin: a randomized, double-blind clinical trial study
od: Hadi Yousefi, et al.
Izdano: (2023)

Women's values and preferences on low-molecular-weight heparin and pregnancy: a mixed-methods systematic review
od: Montserrat León-García, et al.
Izdano: (2022)

COVID-19 in pregnant women after assisted reproductive technologies receiving low molecular weight heparins
od: N. S. Stuleva, et al.
Izdano: (2021)